8-K: ESSA Pharma Sets $80M Distribution Ex-Dividend Date

ESSA Pharma Inc. announced the ex-dividend date and due bill trading procedures for its $80 million return of capital distribution as part of its winding-up and acquisition by XenoTherapeutics, Inc.

Summary

• ESSA Pharma Inc. announced the ex-dividend date for its US$80,000,000 return of capital distribution.
• The distribution is part of the discontinuance and winding-up of ESSA Pharma's business, following its previously announced acquisition by XenoTherapeutics, Inc., a non-profit biotechnology company.
• The Nasdaq Stock Market LLC (Nasdaq) has determined the ex-dividend date for the Distribution will be August 25, 2025.
• The Distribution is scheduled to be paid to Shareholders on August 22, 2025.
• Shareholders will receive approximately $1.69 per Common Share in the Distribution, subject to applicable withholding.
• Because the Distribution represents more than 25% of the price of the Common Shares, Nasdaq has determined that the Common Shares will trade with due bills from August 19, 2025, through and including August 25, 2025 (the Due Bill Period).
• During the Due Bill Period, shareholders who sell their Common Shares will also sell their right to the Distribution, while persons who purchase Common Shares will be entitled to receive the Distribution.

Sentiment

Score: 3

Explanation: The sentiment is low because the company is winding up its business, indicating a cessation of operations as an independent entity. While shareholders receive a cash distribution, it signifies the end of their investment in the ongoing business.

Positives

• Shareholders will receive a significant return of capital, approximately $1.69 per Common Share, totaling US$80,000,000.
• The clear communication of the ex-dividend date and payment date provides certainty for shareholders regarding the distribution.

Negatives

• The company is discontinuing and winding up its business operations.
• The transaction involves the acquisition of all issued and outstanding Common Shares by XenoTherapeutics, Inc., indicating the end of ESSA Pharma as an independent publicly traded entity.

Risks

• Risks related to the proposed timing and completion of the Transaction.
• Uncertainty regarding the amounts payable under the Transaction.
• Risks concerning the timing and receipt of securityholder, regulatory, and court approvals of the Transaction.
• Risks related to the satisfaction of the conditions to the completion of the Transaction.
• Potential for the date of the Special Meeting to change.
• Potential litigation relating to the Transaction that could be instituted by or against ESSA, Xeno, XOMA Royalty Corporation, or their respective directors or officers.
• Risk that disruptions from the Transaction will harm ESSA's business, including current plans and operations.
• Ability to retain and hire key personnel.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction.
• Continued availability of capital and financing and rating agency actions.
• Legislative, regulatory, and economic developments affecting ESSA's business.
• Accuracy of ESSA's financial projections.
• General business, market, and economic conditions.
• Certain restrictions during the pendency of the Transaction that may impact ESSA's ability to pursue certain business opportunities or strategic transactions.
• Unpredictability and severity of catastrophic events, including acts of terrorism, pandemics, outbreaks of war or hostilities.
• Significant transaction costs associated with the Transaction.
• Possibility that the Transaction may be more expensive to complete than anticipated.
• Competitive responses to the Transaction.
• Risks and uncertainties pertaining to ESSA's business as set forth in its Annual Report on Form 10-K dated December 17, 2024, and the definitive proxy statement.
• Unlisted factors may present significant additional obstacles to the realization of forward-looking statements.
• Consequences of material differences in results compared to forward-looking statements could include business disruption, operational problems, financial loss, and legal liability.

Future Outlook

The filing primarily details the mechanics of a previously announced transaction, including a return of capital distribution and the winding-up of the company's business. Forward-looking statements relate to the proposed timing and completion of the Transaction, the amounts payable, and the receipt of necessary approvals. The company's future as an independent entity is ending.

Management Comments

• Buyers and sellers of the Common Shares should consult their broker before trading to be sure they understand the effect of Nasdaq's due bill procedures.

Industry Context

This announcement signifies the exit of ESSA Pharma from the biotechnology industry, specifically its focus on prostate cancer therapies, as it winds up its business and is acquired by a non-profit biotechnology company, XenoTherapeutics, Inc. This is not a typical industry trend but rather a specific corporate action related to the company's strategic decision to cease operations.

Comparison to Industry Standards

• NA

Legal Proceedings

• Potential litigation relating to the Transaction could be instituted by or against ESSA, Xeno, XOMA Royalty Corporation, or their respective directors or officers.

Stakeholder Impact

• Shareholders will receive a cash distribution of approximately $1.69 per share and will no longer hold shares in an operating ESSA Pharma Inc.
• The winding-up of the business implies potential job losses or transfers for employees, though not explicitly stated.
• The discontinuance of the business means the end of ESSA Pharma's development of prostate cancer therapies, impacting potential future patients.
• The winding-up process will involve settling liabilities with creditors, though specific impacts are not detailed.

Next Steps

• Payment of the Distribution to Shareholders on August 22, 2025.
• Completion of the Transaction with XenoTherapeutics, Inc., subject to securityholder, regulatory, and court approvals.
• Settlement of due bill obligations between brokers.

Key Dates

Recommendation

The company is winding up its business and returning capital to shareholders as part of an acquisition. This means the company will cease to exist as an independent operating entity, and shareholders will receive a final cash distribution. Investors should sell to realize the cash distribution or if they do not wish to be part of the final acquisition process, as there will be no ongoing business operations.

Keywords

ESSA Pharma, EPIX, XenoTherapeutics, return of capital, cash distribution, ex-dividend, due bill, Nasdaq, acquisition, winding-up, prostate cancer, biotechnology, pharmaceutical